Back Hepatitis B

Hepatitis B

EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B

Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.

alt

Read more:

EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights

The EASL International Liver Congress is now underway at the Amsterdam RAI congress center. At a Wednesday press conference, EASL officials gave a preview of some of the hepatitis C treatment highlights -- both augmentation of interferon-based therapy and interferon-free regimens -- to be presented at the meeting, which runs through Sunday.alt

Read more:

FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data

The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax Technologies' experimental hepatitis B virus (HBV) vaccine candidate with a toll-like receptor 9 adjuvant, stating it wants to see further data on safety in adults including seniors, the company announced this week.

alt

Read more:

Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis

Heavy drinking can add to the already elevated likelihood that people with liver cirrhosis related to hepatitis B virus (HBV) infection will develop hepatocellular carcinoma (HCC), according to a study published in the April 2013 Journal of Hepatology.

alt

Read more:

Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver

N-acetylcysteine (NAC) administered during recovery of a liver from a deceased donor can help reduce damage during transplantation and increase survival of the liver graft in the recipient, according to a study published in the February 19, 2013, issue of Liver Transplantation.

alt

Read more:

EASL International Liver Congress Starts this Week in Amsterdam

The alt48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.

Read more:

Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection

The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).

alt

Read more:

CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection

Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.

alt

Read more:

HIV+ Less Likely to Respond to Hepatitis B Vaccine, but More Shots Increase Protection

Adults in Kenya responded as well overall to hepatitis B vaccination as people in high-income countries. People with HIV had poorer response, but this could be mostly overcome with repeated doses, according to a study described in the February 1, 2013, Journal of Infectious Diseases.

alt

Read more: